Dhampur Bio Organics signs exclusive Mycoprotein tech license with Planetary SA
Dhampur Bio Organics Limited has signed an exclusive Technology Licensing Agreement with Planetary SA, Switzerland, for Mycoprotein production in India. DBO will pay a 10% royalty on after-tax revenue quarterly. The agreement has a 10-year initial term and is expected to create a new revenue stream.
This is a significant development as it marks the company's entry into a new business vertical with exclusive rights and potential for substantial revenue and profit growth.
The agreement is positive as it grants exclusive rights for a new product in India, involves a strategic partnership, and is expected to create a new revenue stream and enhance profitability.
Dhampur Bio Organics Limited (DBO) has officially entered into a Technology Licensing Agreement with Planetary SA, Switzerland, on October 19, 2026, at 2:30 pm (IST). This agreement grants DBO the exclusive rights for the production of Mycoprotein in India.
This follows a non-binding term sheet signed between the two companies on January 21, 2026. The agreement outlines the terms for constructing and operating Mycoprotein production infrastructure by DBO, with Planetary SA acting as the technology provider and off-taker. DBO will serve as the manufacturer and supplier of Mycoprotein and related products. Additionally, the parties intend to execute a commercialization and offtake agreement, as well as a joint venture agreement to establish a Joint Venture Company for the commercialization and offtake of Mycoprotein in India.
The financial terms include a royalty of 10% of after-tax revenue, paid quarterly by DBO to Planetary. A one-time launch fee will be charged by Planetary for engineering, launch, installation, commissioning, process training, and handover support on an open-book basis. DBO will also pay a one-time IT setup fee for the configuration of the Data Platform.
Planetary SA's key obligations include providing licensed intellectual property and services, engineering support, and maintaining the licensed intellectual property. DBO's key obligations involve using the licensed intellectual property solely for the project, making payments, adhering to confidentiality, and obtaining necessary approvals.
The agreement has an initial term of 10 years from the Effective Date, with potential renewals for successive 5-year terms upon mutual written agreement. This venture does not involve any related party transactions. The rationale behind this agreement is the synergy with DBO's existing business, serving as a forward integration step where sugar and molasses will act as feedstock for Mycoprotein production. This new business is expected to introduce a new revenue stream and enhance the company's profitability.
What to do with a filing like this
Dhampur Bio Organics Limited filed this with the NSE as a statutory disclosure, categorised under strategic partnerships. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dhampur Bio Organics Limited. Read the original for the full detail.